VIR - Company ID 0001706431
The table below shows Vir Biotechnology, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$132.39M | -$78.12M | -$109.39M | -$125.78M | $550.09M | -$89.53M |
| Capital expenditure | $390.00K | $1.63M | $1.87M | $6.87M | $15.84M | $667.00K |
| Investing cash flow | $11.84M | $126.82M | $28.42M | $98.08M | -$105.39M | $87.53M |
| Dividends paid | - | - | - | - |
Vir Biotechnology, Inc. reported operating cash flow of -$391.78M for fiscal year 2025. That is up 12.2% from -$446.35M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$66.38M (FY 2017) to -$391.78M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $162.52M | $598.00K | $152.00K | $2.34M | $27.68M | $87.50M |